Human Keratin, type II cuticular Hb1 (KRT81) ELISA Kit

Category: Assay Kits
Catalog
AE36242HU
(Ships in 5-10 business days)

Questions? Contact us

Call (800) 832-2611

arp-guarantee
- +
$0.00
More Information
Product Name Human Keratin, type II cuticular Hb1 (KRT81) ELISA Kit
Description KRT81 is a member of the keratin gene family. As a type II hair keratin, it is a basic protein which heterodimerizes with type I keratins to form hair and nails. The predicted 495-amino acid HB1 protein has an 88-amino acid C-terminal domain. The amino acid sequences of human and sheep HB1 are 90% identical. Northern blot analysis detected HB1 transcripts in human scalp but not unhaired breast epidermis. HB1 is more closely related to HB3 and HB6 than to HB5. In situ hybridization studies demonstrated that type II keratin genes are sequentially activated in the hair follicle in the following order: HB5--(HB1, HB3)--HB6. Both HB1 and HB3 mRNA syntheses begin 10 to 15 cell layers above the apex of the dermal papilla and end abruptly in the middle of the cortex. This assay has high sensitivity and excellent specificity for detection of Human KRT81. No significant cross-reactivity or interference between Human KRT81 and analogues was observed.
Synonyms HB1, Hb-1, KRTHB1, MLN137, ghHkb1, hHAKB2-1, hard keratin, type II, 1|keratin, hair, basic, 1
Method Sandwich ELISA
Detection Range 0.156-10 ng/mL
Sensitivity 0.053 ng/mL
Reactivity Human
Sample Types Serum, Plasma, Other biological fluids.
Background KRT81 is a member of the keratin gene family. As a type II hair keratin, it is a basic protein which heterodimerizes with type I keratins to form hair and nails. The predicted 495-amino acid HB1 protein has an 88-amino acid C-terminal domain. The amino acid sequences of human and sheep HB1 are 90% identical. Northern blot analysis detected HB1 transcripts in human scalp but not unhaired breast epidermis.
HB1 is more closely related to HB3 and HB6 than to HB5. In situ hybridization studies demonstrated that type II keratin genes are sequentially activated in the hair follicle in the following order: HB5--(HB1, HB3)--HB6. Both HB1 and HB3 mRNA syntheses begin 10 to 15 cell layers above the apex of the dermal papilla and end abruptly in the middle of the cortex.
Supplier Abebio

All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.